Board of directors

Thomas Werner, Ph.D.

Vice-chairman of the board of directors

Nationality: German | Year of Birth: 1956

Thomas Werner, Ph.D., has been a member of the board since 2011 and has been serving as the vice-chairman of the board since 2018. He is also chairman of the corporate governance & nomination committee and a member of the compensation committee. He is independent in accordance with the Swiss Code of Best Practice for Corporate Governance.

Mr. Werner served as senior vice-president and managing director of Glaxo SmithKline Germany from 2001 to 2008. From 1997 to 2000, he was managing director for Glaxo Wellcome Germany and director of the Central European Region. Previously he was managing director of Bristol-Myers Squibb Germany and of Convatec Central Europe.

Mr. Werner serves as the chairman of the investment advisory committee of the Health for Life Capital Fund (HFL I and II) of Seventure Partners and as chairman of the board of Pharmathen S.A. He was chairman of the board of Fertin Pharma A/S from 2017 to 2019 and senior independent non-executive director/vice-chairman of Vectura Group plc (previously SkyePharma plc) from 2009 to 2021.

Mr. Werner graduated with a doctorate in chemistry from the University of Göttingen, Germany.